Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 24 Ovarian Neoplasms 16 Lung Neoplasms 15 Breast Neoplasms 14 Endometrial Neoplasms 13 Parkinson Disease 4, Autosomal Dominant Lewy Body 12 Fallopian Tube Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 8 Neoplasm Metastasis 8 Triple Negative Breast Neoplasms 5 Esophageal Neoplasms 5 Adenocarcinoma Of Esophagus 5 Stomach Neoplasms 4 Neoplasms 4 Melanoma 4 Esophageal Squamous Cell Carcinoma 4 Colorectal Neoplasms 3 Carcinoma 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Peritoneal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Transitional Cell 2 Brenner Tumor 2 Anatomic Stage I Breast Cancer AJCC v8 2 Advanced Solid Tumour 2 Adenocarcinoma, Bronchiolo-Alveolar 2 Adenocarcinoma of Lung 2 Adenocarcinoma 2 Uterine Neoplasms 1

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × Paclitaxel × 30 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡